ECHA suspends processing chromates applications


In January 2026 ECHA communicated to ADCR that they will suspend processing of the Review Reports ADCR submitted to ECHA in 2024 (see table of Tranche 2 submissions on ADCR and Chromates Reauthorisation). ADCR Tranche 2 Review Reports covered three substances and four uses. The reason for ECHA’s suspension is directly related to the ongoing restriction process of Cr(VI) substances under REACH.  

For all Review Reports submitted by ADCR, the use can continue under transitional measures according to REACH Article 61.1, until the future Cr(VI) restriction enters into force, or until the European Commission makes a different decision.
Other news items:

19 November 2026
ECHA's Committee on Socio-economic Analysis (SEAC) adopted its final opinion on Cr(VI) restriction in their November meeting, and ECHA published news and extracts of action points today, 19 November 2026. SEAC concludes that the restriction options (RO1 and RO2) can be proportionate if the transitional period of 36 months for RO1, and longer than 36 months if RO2 are used. SEAC says that RO1 is having minor costs and very limited benefits and SEAC considers that RO2 is the option with the highest benefits that is still likely to be proportionate and practical. If a harmonised LV is preferred by the decision maker and distributional impacts are factored in by them, a uniform limit of 0.5 µg/m3 (in combination with ELVs of RO2) could also be an appropriate option. However, SEAC cannot come to a conclusion on whether a restriction is the most appropriate risk management option overall. ECHA has indicated that they will publish the opinion in the next few weeks. See ECHA news and extracts from the SEAC action points .
Show More